Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

USA Benefits Group Partners with AmeriLife to Expand Agent Opportunities & Serve More Clients

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that it has partnered with USA Benefits Group, a fast-growing, national health brokerage dedicated to delivering the highest quality products, service, and support to independent agencies, agents, and their clients. Per the agreement, terms of the deal were not disclosed. “We see this partnership as a power play to further USA Benefits Group's explosive growth,” said Rick Banville, CEO of USA Benefits Group. “AmeriLife is a rapidly expanding giant in the industry who takes the pressure off of agencies like ours through resources like HR, payroll, compliance, legal, marketing, recruiting, and technology so we can do what we do best: recruit and train agents and agencies to be successful. We are very excited about our bright future together.” “We are so grateful and honored to become partners with AmeriLife,” added Jessica Banville, president of USA Benefits Group. “We are thrilled that our agents and clients will benefit from an even larger portfolio of products and support. This partnership will give us even greater opportunity in making the industry better as we continue to develop training systems that bring success to all. We are stronger together!” For more than three decades, USA Benefits Group has been at the forefront of helping agents and their clients navigate the complexities of health and ancillary insurance (including ACA and ACA alternatives) for the under-65 market. Over the years, the company has expanded its portfolio to include Medicare Advantage and Medicare Supplement insurance, life insurance, and health insurance benefits for small businesses, as well as developed proprietary tools and training for its insurance professionals to succeed and thrive. Headquartered in nearby Spring Hill, Fla., USA Benefits Group boasts nearly 2,000 independent contracted agents nationwide. Now, with access to AmeriLife’s best-in-class resources, deep product portfolio, and industry expertise and leadership, USA Benefits Group is primed to supercharge its growth and deliver even more value to beneficiaries across the United States. “I’m excited to welcome Rick, Jessica and the USA Benefits Group family to ours,” said Scotty Elliott, Chief Distribution Officer for AmeriLife Health. “Our shared values and commitment to excellence in service makes this a winning partnership right out of the gate, and I can’t wait to see what we can accomplish together.” ### About USA Benefits Group USA Benefits Group is a nationwide insurance agency dedicated to the principles of service, integrity, professionalism and diversity. The company provides an extensive range of insurance products and pledges to honor its commitment to its producers, clients and carriers by holding itself to the highest ethical standards. Everything that USA Benefits Group does is designed to ensure that its customers are presented quality products with a “Servant’s Heart” and a goal of exceeding expectations. For more information, visit USABG.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as a leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

December 11, 2023 10:10 AM Eastern Standard Time

Faron Pharmaceuticals presents "very positive" Phase 1 data at ASH Conference

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical stage biopharmaceutical company announced "very positive" Phase 1 data from the ongoing BEXMAB study in myeloid malignancies. The data is being presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition taking place until tomorrow, December 12, 2023, in San Diego, California, and virtually. Jalkanen says the data reveals a promising response in patients, especially in inducing myeloid differentiation in Myelodysplastic Syndrome (MDS), a condition with limited treatment options Typically, patients with this type of cancer have a life expectancy of around 24 months, making these results particularly significant. Investors and shareholders have responded positively to this latest news, as the trial shows a response rate potentially 5 to 10 times higher than the current standard of care. Faron Pharmaceuticals is now preparing to advance to the next trial phases and is exploring potential partnerships. Regarding the company's overall performance in 2023, Dr. Jalkanen expresses satisfaction with Faron's ability to maintain and even increase its pace, with promising data accumulating from ongoing trials and the initiation of new ones. The company is targeting a marketing approval application by 2025, staying on track with its previously set goals. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 11, 2023 10:09 AM Eastern Standard Time

Video

PathPresenter Selected by Cincinnati Children’s to Provide Comprehensive Digital Pathology Workflow Solution

PathPresenter

PathPresenter, the global image sharing platform for pathology, was recently selected by Cincinnati Children’s to provide an integrated digital pathology workflow solution to meet the health system’s requirements across clinical care, remote consultations, education, and research. Cincinnati Children’s, which ranks No. 1 in the nation in U.S. News & World Report’s listing of Best Children’s Hospitals for 2023-24, recently completed an extensive selective process to procure a comprehensive digital pathology workflow solution. Cincinnati Children’s, utilizing PathPresenter’s platform, seeks to improve workflow efficiencies (enabled by tight integration with its laboratory information system); expand its digital consultation network; provide new educational capabilities to advance clinical competency testing; and enable enhanced research capabilities with the ability to connect any type of AI algorithm – from 3 rd party vendors or developed in-house. PathPresenter is a secure and scalable multi-tenant enterprise workflow platform that has been developed by pathologists with deep domain knowledge and experience. Trusted by 45+ tier-one institutions, PathPresenter is the most comprehensive suite available for clinical care, remote consultations, education, and research. With expert guidance in storage optimization, tight integration with LIS systems through a proprietary HL7 engine, and robust incorporation of 3 rd party and in-house-built AI algorithms, PathPresenter ensures genuine value to institutions – without the marketing noise. While Cincinnati Children’s doesn’t endorse or sponsor any commercial products, services, or companies, Dr. Jennifer Picarsic, MD, director of Digital Pathology and AP Informatics at Cincinnati Children’s, noted that a successful digital pathology program relies not just on scanning and viewing digital slides, but rather a re-imagined vision for how pathology will be practiced in the future. “As pathology leaders, we seek to build a new digitally integrated workflow that will enhance clinical, education and research opportunities to facilitate new innovations and wider access to our expert pathologists from anywhere in the world,” Picarsic said. Dr. Rajendra Singh, founder of PathPresenter, added “We are honored to work with the excellent clinical and technical teams at Cincinnati Children’s, given their thorough understanding and deep knowledge of what they need from a workflow provider with a complete focus on improving efficiencies ensuring better care of their precious patients. PathPresenter was created to fill in the gaps in use of digital pathology, and this further fulfills our mission.” About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer, Dr. Rajendra Singh, PathPresenter has been adopted by 45+ tier one medical institutions for clinical care, remote consultations, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. For more information visit www.pathpresenter.com. Contact Details Cory Batenchuk +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.com

December 11, 2023 09:00 AM Eastern Standard Time

Research Shows New Single-Use Protein A Capture Technology Offers 10X Productivity Over Standard Resin Columns for Antibody Purification

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new research paper from its global research and development Center (R&D Center) titled, Building a Fully Single-Use Process: High Productivity Protein A Membrane Devices that Complement Disposable Upstream Technology. In the research, the CDMO’s scientists feature exclusive data on the promise of new single-use devices that alleviate common monoclonal antibody (mAb) purification problems that can occur when using standard Protein A resin columns. The new research is available immediately and offers biopharma developers a glimpse into the promise of single-use technology for the Protein A membrane capture chromatography step, using the GORE® Protein Capture Devices with Protein A as a technology use case. The paper also features conclusions on the benefits of this innovative technology, such as reduced manufacturing footprint, reduction in lead-time and consumable costs, and more. There are several important topics covered in the study, including: Overview of protein A capture technology: A recap of the promise offered by single-use membrane chromatography technologies; including their ability to operate with a high flow rate and achieve high productivity and disposable process; featured performance data on manufacturing scales of Protein A membrane devices, including small scale and manufacturing scale comparisons. Benefits single-use devices offer to the manufacturing process: When paired with single-use bioreactor upstream strategies, the research found contamination risk, operation time relating to preparation and cleaning, and operator error were all reduced. The technology also offers cost savings, reduced risk, lower bioburden, greater speed to market, and other benefits. Purification productivity data: single-use devices vs. standard resin: Protein A membrane devices showed 10 times higher productivity than the Protein A resin column on the purification of mAb cultures. Other data includes productivity details, including removal of host cell proteins (HCP) and host cell DNA, when compared with resin columns, reduction in bioburden, time savings, and more. R&D review: implementing protein A membrane device into traditional manufacturing flows: A review of the implementation process for these devices and how they can be implemented for all vessels and into existing flow-paths, the ion exchange membrane device, and single-use TFF membrane capsules, while improving efficiencies to purify mAb in a short process time. The AGC Biologics R&D Center focuses on modernizing and advancing processes and technologies used for biopharmaceutical development and manufacturing capabilities. The scientists within the team are responsible for developing and implementing new procedures and evaluating innovations that help developers of protein biologics and advanced therapies improve titers/yields, cell line development, downstream purification analytical analysis, and more. To learn more about AGC Biologics visit https://www.agcbio.com/. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

December 11, 2023 06:03 AM Eastern Standard Time

Epicenter of Healthcare Transformation: The Intelligent Health Association's 2023 International Summit starts tomorrow, Monday, December 11

1BusinessWorld

In an era where technological evolution is pivotal to healthcare advancements, the Intelligent Health Association (IHA) proudly announces the launch of its 2023 International Summit. This year's summit, occurring from December 11 to December 15, 2023, represents a paradigm shift in healthcare conferences. Embracing a fully virtual format, the summit ensures accessibility for all, enabling professionals globally to engage with leading healthcare insights without the constraints of physical attendance. https://1businessworld.com/2023-intelligent-health-summit/ Reimagining Healthcare Through Digital Transformation The Intelligent Health Association is at the forefront of orchestrating an event that mirrors the current landscape of healthcare - a blend of technological innovation and practical applications. This summit is not just an event; it's an intellectual symposium, bringing together the brightest minds to discuss, debate, and shape the future of healthcare. Key Topics and Educational Excellence Over the course of five days, the summit will delve into critical areas such as AI's impact on healthcare, cybersecurity in patient data management, advancements in telehealth, the imperatives of health equity, and the integration of innovative technologies in healthcare settings. Each day is meticulously crafted to offer a comprehensive understanding of these key areas: - Exploring the role of AI in enhancing healthcare delivery. - Navigating the complexities of data and cybersecurity in healthcare. - Evaluating the evolution of telehealth in a post-pandemic era. - Championing the cause of global health equity. - Understanding the necessity of change management in adopting new technologies. A Commitment to Continuing Medical Education In an effort to empower healthcare professionals worldwide, the IHA, in collaboration with the Weitzman Institute, is offering Continuing Medical Education (CME) credits for this summit. This initiative underscores our commitment to ongoing professional development in the healthcare sector. Leadership Insights and Global Collaboration Harry P. Pappas, Founder and CEO of the Intelligent Health Association, emphasizes the summit's role in shaping healthcare's future. "This summit represents a confluence of thought leadership and innovative practices that are essential for the evolution of healthcare. We are creating a forum where ideas meet implementation," remarks Pappas. Echoing this sentiment, Sherri Douville, CEO at Medigram and Co-Chair of the Intelligent Health Summit, highlights the summit's multidisciplinary approach. "Our objective is to forge a nexus of technology, policy, and healthcare. This summit is a testament to our dedication to driving healthcare forward through leadership and transformation," states Douville. Invitation to Join a Transformative Journey The Intelligent Health Association extends an invitation to healthcare professionals, industry experts, policymakers, and academicians to join this groundbreaking event. The fully virtual format of this summit opens doors for a global audience, making it an inclusive and easily accessible platform for sharing and learning. Together, we can chart a new course for healthcare that is more adaptive, equitable, and innovative. https://1businessworld.com/2023-intelligent-health-summit/ All news and content distribution in partnership with News Direct. About the Intelligent Health Association: The Intelligent Health Association (IHA) is a global consortium of healthcare and technology leaders committed to advancing digital healthcare. Our goal is to disseminate unbiased information on innovative technologies that enhance patient care and improve clinical and business processes. The IHA champions the transformation of healthcare through high-quality educational programs and networking events, facilitating the adoption and implementation of new technologies in health and wellness ecosystems. We are dedicated to reshaping healthcare through innovation and leadership, ensuring a future where technology seamlessly integrates with patient care. Intelligent Health Association About 1BusinessWorld: 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

December 10, 2023 02:04 PM Eastern Standard Time

Image

News Release

Senzime's CEO shares breakthrough patient monitoring technology for safer surgeries

Senzime

Senzime CEO Phillip Siberg joined Steve Darling from Proactive from the OTC studio in New York City to shed light on the innovative solutions offered by Senzime, aimed at significantly enhancing patient safety during and post-surgery through the power of advanced algorithms. Senzime's impressive array of tools, such as the TetraGraph and ExSpiron 2Xi, leverage real-time monitoring of neuromuscular and respiratory functions—crucial parameters during and after surgical procedures. The overarching objective of these cutting-edge technologies is to reduce in-hospital complications dramatically and drive down healthcare costs associated with surgical and high-acuity procedures. One exciting development that Siberg shared is Senzime's success in securing multiple new orders for the TetraGraph system, particularly from several prestigious German university hospitals. The German market has proven to be a strong and fruitful one for Senzime, with the company already having secured nearly 30 major hospital contracts, including pivotal partnerships with key robotic surgery centers. This expansion and adoption of Senzime's technology underscore the growing recognition of the transformative potential of their solutions within the medical community. With a robust growth trajectory, Senzime aims to achieve $30 million in sales by 2025, with the US being a pivotal market. The company's strategic move to cross-trade on the OTCQX provides accessibility to US capital markets, facilitating increased shareholder participation. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

December 08, 2023 01:25 PM Eastern Standard Time

Video

UDS Earns Highest Accreditation from NCQA for the Third Time in a Row

UDS

United Disabilities Services (UDS) Foundation is thrilled to announce that their Home and Community-Based Services (HCBS) Care Management program has received the highest accreditation from the National Committee for Quality Assurance (NCQA) for the third time in a row. The non-profit, committed to helping older adults, veterans, and people with disabilities lead more independent and fulfilling lives, offers services to those with a range of social and pragmatic needs, like transportation, housing, nutrition, isolation, emotional well-being, and medical problems. NCQA is an independent 501(c)(3) nonprofit organization that improves healthcare quality through accreditation and certifies a wide range of healthcare organizations promoting high-quality care and recognizing high-performing health plans and providers. Evaluated on eight standards that must be met at the highest level for policy and procedures, UDS achieved 100% in the strenuous chart audit review. UDS was one of the first to achieve Long-Term Services and Supports (LTSS) Care Management accreditation from NCQA in 2017 when it was initiated. They were awarded the highest level with a full three-year time frame and then, in 2020, again awarded the full three-year accreditation. Now, in 2023, they have achieved it once more with an A+ rating. William Kepner, the President and CEO of UDS, says, “We are delighted and proud to have once again achieved the highest accreditation from NCQA who have developed excellent standards of care. Our goal is to always provide a great customer experience and outcome, which starts with providing exceptional quality care. I am proud of our UDS support coordination team for their continuing high quality of care and support for those we serve.” We invite you to visit the UDS website at www.udservices.org to learn more about the company and its mission and services. UDS Foundation is a Lancaster, PA-based organization whose mission is to improve the lives of older adults and individuals with disabilities. UDS Foundation accomplishes that by providing a variety of home- and community-based services to help people enjoy safer, happier, and more independent lives in the comfort of their homes. Incorporated in 1970, UDS Foundation has evolved from a small organization to a company providing a network of 12 different programs through several nonprofit entities. UDS Foundation serves older adults, individuals with disabilities, and veterans throughout Pennsylvania and coordinates a network of business partners and satellite offices in multiple counties. For more information, visit www.udservices.org. Contact Details Debra Showalter +1 717-286-0047 madison@rprfirm.com Company Website https://udservices.org

December 08, 2023 11:20 AM Eastern Standard Time

Image

G-NiiB Oral Microbiome Immunity Formula SIM01 Alleviates Post-COVID-19 Conditions

G-NiiB GenieBiome

HONG KONG SAR - Media OutReach Newswire - 8 December 2023 - Hong Kong's leading biomedical and microbiome technology company, G-NiiB GenieBiome, is pleased to announce that a ground-breaking large-scale randomised, double-blind, placebo-controlled clinical trial ("the Trial") conducted on the efficacy of SIM01, an oral microbiome immunity formula developed by a top-notch medical school in Hong Kong, involving 463 patients who had contracted COVID-19, has strongly proved that the consumption of SIM01, an oral microencapsulated live bacteria formula, could significantly improve the gut microbiota after six months and lead to remarkable alleviation of post-COVID-19 sequelae ("long COVID"), encompassing a range of symptoms affecting different systems and organs. The findings of the Trial were published yesterday in The Lancet Infectious Diseases, the most authoritative international medical journal in infectious diseases. G-NiiB GenieBiome’s flagship product, G-NiiB Immunity+, contains the oral microbiome immunity formula SIM01. The Trial has robustly demonstrated the exceptional efficacy of SIM01 in alleviating post-COVID-19 conditions, sending a significant breakthrough and a sliver of hope for the 65 million individuals worldwide who have been profoundly impacted by the long COVID. It is widely acknowledged that post-COVID-19 symptoms exhibit substantial interindividual variability, complexity, and long-haul span, posing a dual challenge to the patient's physiological and psychological well-being. Given the current lack of targeted and effective therapies, it has emerged as one of the most formidable health challenges in the aftermath of the COVID-19 pandemic. In its August 2021 publication, The Lancet mentioned that long COVID is the primary challenge of modern medicine. The oral microencapsulated live bacteria formula SIM01, published in The Lancet Infectious Diseases this time, is the flagship product of G-NiiB GenieBiome. Multiple clinical studies have confirmed its effectiveness. This very study, known as the RECOVERY study, is the first global clinical research to testify that SIM01 can improve gut microbiota and effectively alleviate post-COVID-19 symptoms, including fatigue, memory loss, difficulty in concentration, gastrointestinal upset and general unwellness. The study results further highlight the interconnectedness of the "Microbiome-Gut-Brain Axis," illustrating how probiotic metabolites absorbed through the gut can contribute to improving brain function. This also underscores the potential of restoring healthy gut microbiota as a novel intervention and strategy for addressing post-COVID-19 neurological symptoms. The publication of these research findings in The Lancet Infectious Diseases signifies authoritative recognition of their scientific and pioneering property, as well as a strong affirmation of SIM01's possibility to improve post-COVID-19 symptoms and enhance overall immune performance in patients. Ms. Rachel Fan, CEO of G-NiiB GenieBiome, stated, "The publication of the Trial on G-NiiB's microbiome immunity formula, SIM01, in the medical journal The Lancet Infectious Diseases, is undoubtedly a scientific feat and a significant milestone for G-NiiB GenieBiome. It represents a great recognition of the leadership, judgment, and expertise of our founder and Chief Scientific Advisor, showcasing our leading position and innovative capabilities in microbiome research. It also serves as a strong testimony of our professional competence and product quality, demonstrating that our core technology has received authoritative approbation from the international medical community. This is considerable progress and an outstanding achievement for a pioneering company to keep a foothold in the microbiome arena. We are immensely proud." Besides, "The practical significance of this study lies in proving the scientific efficacy and multiple feasibilities of SIM01, inaugurating new avenues for microbiome research and human health exploration. From a societal perspective, G-NiiB's microbiome immunity formula, SIM01, presents the potential to offer a fresh choice for individuals suffering from long COVID while making seminal contributions to the fight against COVID-19 and other diseases. G-NiiB GenieBiome is committed to continuing its investment in innovative research and cutting-edge development, steadfastly striving to improve human health and tackle various disease challenges." Ms. Rachel Fan, CEO of G-NiiB GenieBiome, background is the clinical trial published in The Lancet Infectious Diseases. Utilising advanced metagenomic sequencing data, patented artificial intelligence, and microencapsulation technology, G-NiiB GenieBiome has introduced three patented oral microbiota formulations. They are SIM01, a microbiome precision immunity formula designed to enhance the immune system; SMT04, a microbiome precision gut protective formula to preserve intestinal health; and SIM03, a microbiome precision children immunity formula to develop diverse rainbow immunity. Clinical data from a renowned medical school in Hong Kong have supported these formulations. The team is currently researching to develop innovative formulations to treat and alleviate complex conditions such as fatty liver and adult eczema, aiming to meet the evolving needs of the health supplement market. Ms. Rachel Fan further added, "Our core team members excel in their respective spheres. Our collective goal is to blaze innovative transformation in the field of human health through microbiome research. By leveraging the leap we made in microbiota research, the team strives to significantly improve disease prevention, diagnosis, and treatment, sequentially accelerating the transition into a new era of microbiota-centric medicine." G-NiiB GenieBiome G-NiiB GenieBiome is a biotechnology company founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science to tackle a myriad of diseases, including colorectal cancer, obesity, atopic eczema, autism, and mood disorders, revolutionizing the prevention, diagnosis, and treatment of disease. Our precision portfolio of G-NiiB includes diagnostic and risk prediction tests, next-generation microbiome precision formulas, and precision medicine tailored for the Asian population. Our vision is to be a game changer in human health with microbiome solutions. Contact Details Tim Chan timchan@g-niib.com Company Website https://www.g-niib.com

December 08, 2023 09:00 AM Eastern Standard Time

Image

AI-Driven Media Discovery, Distribution and Monetization Platform VideoXRM Launches Netcapital.com Funding Campaign

VideoXRM

VideoXRM, the pioneering artificial intelligence (AI) driven, B2B video distribution and discovery platform, announces the launch a $500,000 offering on the Netcapital.com digital private capital markets ecosystem. Capital from the offering will be used for the continued development and commercialization of the VideoXRM platform. The minimum investment is $300 and the offering deadline is January 31, 2024. Learn more at: https://netcapital.com/companies/videoxrm Businesses increasingly utilize video and rich media to differentiate their benefits and to reach new audiences, yet most of this complex and unstructured content remains difficult if not impossible to find. VideoXRM brings expanded exposure and ROI to this high value content, that until now, has been virtually inaccessible via conventional search technologies. Utilizing proprietary AI-machine learning technology, metadata, and granular indexing, VideoXRM is able to automatically classify videos, audio, images, etc., enabling unparalleled media discovery. The platform is ideal for company to company and company to investor engagement, news media, researchers, supply chain and procurement managers, M&A sourcing, partnering and benchmarking. VideoXRM’s revenue streams will include promotional services, highly targeted video campaigns and premium content on a pay-per-view and pay-per-subscription basis. Initial revenue is targeted by year-end 2023. VideoXRM CEO, David N. Baker, commented, “Over the past 2 ½ years we have made huge progress building out the platform and business solely with internal funding. Our accomplishments include: Commercial Launch of the VideoXRM Platform Attracting 175 companies and 9,000 videos to the platform, with many content sources in the pipeline. Developing proprietary AI/Machine learning technology to extract video and audio metadata used to classify and index content within 140,000 industry categories. 2 Patents Issued and 3 Pending. “We are launching our Netcapital offering to fund our continued growth and enhancement of our platform. In Q1 2024 we will launch an entirely new aspect of our video platform, providing capabilities that will add substantial additional value for our customers and company. We hope you will join us on our journey to build the most powerful business media distribution and discovery platform to enable the leg of growth in video and rich media communications and commerce.” Connect with us on LinkedIn and Twitter and Facebook. About VideoXRM ( VideoXRM.com ) VideoXRM is an AI-driven, B2B media discovery, distribution, communication and monetization platform that connects corporate rich media content with all potential stakeholders. The platform and smart search technology creates value and knowledge from mountains of unstructured digital media, delivering greater ROI from content investments. VideoXRMâs mission is harnessing the enhanced communicative power of rich media through a new distribution and discovery paradigm. VideoXRM was Co-founded by David N. Baker, who formed Revere Data LLC (Sectorbase) which was acquired by FactSet Data Systems, Inc. His Co-founders are Vadim A. Tarasov, Byron Kwok, and David Guzy. Contact Details Catalyst IR David C. Collins +1 212-924-9800 videoxrm@catalyst-ir.com Company Website https://videoxrm.com

December 08, 2023 08:20 AM Eastern Standard Time

1 ... 68 69 70 71 72 ... 307